Research summary · UCL 2026

The UK Aesthetics Industry in 2026: What the Data Shows

In February 2026, researchers at University College London published the most comprehensive mapping of the UK aesthetic medicine industry to date. The study documented 19,701 practitioners operating across 5,589 clinics nationwide.

Scale and growth

The UK aesthetics industry has grown faster than almost any comparable healthcare-adjacent sector. The study documented a 437% increase in practitioners over two years — from an estimated 3,600 in 2023 to 19,701 in 2026.

That growth is not evenly distributed across practitioner types.

Practitioner typeShareChange since 2023
Medical aestheticians (doctors, nurses, dentists)~75.2%Stable
Non-medical aestheticians24.8%Doubled (from ~12%)

Non-medical aestheticians — practitioners with beauty or aesthetics training rather than a medical or prescribing qualification — now account for roughly 1 in 4 practitioners. That proportion doubled in the space of two years.

Why this matters: Botox (botulinum toxin type A) is a prescription-only medicine under UK law. A non-medical aesthetician cannot prescribe it independently — they operate under a remote prescribing arrangement that is legal, but structurally different from being treated by the person who assessed and prescribed for you. Dermal fillers are not prescription drugs in the UK and remain largely unregulated, which means the choice of practitioner — not the regulatory status of the product — is the dominant safety gate.

Pricing

The study analysed pricing data from practitioners across the UK using botulinum toxin as the reference treatment.

Practitioner typeAverage price
Doctor / prescribing clinician£187
Non-medical aesthetician£148

The gap is 32–38% depending on location, with the widest spreads in London and the South East. The price difference reflects structural differences in accountability, insurance scope, and prescribing rights — not simply brand positioning or clinic prestige.

Geography and deprivation

The study cross-referenced practitioner locations against the Index of Multiple Deprivation (IMD), dividing the UK into five quintiles from most-affluent (Q1) to most-deprived (Q5).

The headline finding: practitioner density is 6.7 times higher in the most-deprived quintile than the least-deprived.

This sounds like better access. In practice, it reflects a different composition of practitioners and settings. The study found that beauty-salon-administered botox peaks not in Q5 (most deprived) but in Q3 — the middle deprivation band — with an odds ratio of 2.18 compared to Q1.

In mid-deprivation postcodes, you are more than twice as likely to be receiving a prescription injectable in a beauty-salon setting than in an affluent area.

Beauty salon settings are not automatically unsafe, but they typically lack the clinical governance infrastructure — emergency protocols, resuscitation equipment, medical indemnity — that a regulated clinic or medical practice carries. Read our safety guide for what to look for when verifying a clinic.

The regulatory context (2025–2026)

The growth figures sit against a rapidly shifting regulatory backdrop.

July 2025

The UK Health Security Agency (UKHSA) issued a national alert following a cluster of botulism cases linked to non-medical aesthetic treatments, warning about unlicensed botulinum toxin products.

August 2025

The UK government announced a proposed tiered classification system — commonly referred to as the “Amber tier” — requiring more stringent practitioner standards for injectable treatments. This reform had not been enacted as of the Zargaran study’s publication date.

England only: Regulatory changes announced in 2025 apply primarily to England. Scotland, Wales, and Northern Ireland have separate regulatory frameworks that may diverge in timeline and scope.

Four questions before any aesthetic appointment

The Zargaran study doesn’t tell you who to book. But it does clarify what structural safeguards to ask about.

1. What are your qualifications and which regulatory body are you registered with?

Look for registration with the Nursing and Midwifery Council (NMC), General Medical Council (GMC), or General Dental Council (GDC) for medical practitioners. For non-medical practitioners, voluntary registers such as JCCP or Save Face provide a baseline.

2. Who prescribes for you, and will they be present at my appointment?

If the practitioner is non-medical, they require a prescription from a third party. Ask whether that prescriber will review you directly — in person or via video consultation — not simply countersign a form.

3. What level of indemnity insurance do you hold?

Medical practitioners carry medical indemnity. Non-medical practitioners carry beauty or aesthetics insurance, which covers a different scope of complications. Know which you're getting.

4. What is your emergency protocol if a complication occurs?

Vascular occlusion (where filler blocks a blood vessel) is rare but time-critical. Ask whether the practitioner carries hyaluronidase — the antidote for filler complications — and what their escalation pathway is.

Find a verified clinic

SkinSage lists aesthetic clinics that meet our verification standards across the UK — including in areas where finding a verified option requires more effort.

Find a verified clinic near you →

About this research

Full citation: Zargaran A, et al. “Mapping the UK Aesthetic Medicine Industry: Practitioner Profiles, Pricing, and Socioeconomic Gradients in Botulinum Toxin Practice.” Aesthetic Surgery Journal Open Forum, 8(1), February 2026. DOI: 10.1093/asjof/ojag006

Open-access (CC BY 4.0). Full paper available free of charge via the DOI above.

References cited in the study

  1. 1.GOV.UK. Consultation launched into unregulated cosmetic procedures. gov.uk
  2. 2.GOV.UK. Review of the Regulation of Cosmetic Interventions. gov.uk
  3. 3.GOV.UK. UKHSA issues warning over botulism. gov.uk
  4. 4.Zargaran D, Zoller F, Zargaran A, et al. Complications of cosmetic botulinum toxin A injections to the upper face: a systematic review and meta-analysis. Aesthet Surg J. 2022;42:NP327–NP336. DOI: 10.1093/asj/sjac036
  5. 5.Zargaran D, Zoller FE, Zargaran A, Mosahebi A. Complications of facial cosmetic botulinum toxin A injection: analysis of the UK MHRA registry and literature review. J Plast Reconstr Aesthet Surg. 2022;75:392–401. DOI: 10.1016/j.bjps.2021.05.074
  6. 6.Mahase E. UK government promises crackdown on “cowboy cosmetic procedures” amid rise in rogue providers. BMJ. 2025;390:r1668. DOI: 10.1136/bmj.r1668
  7. 7.GOV.UK. Licensing of non-surgical cosmetic procedures. gov.uk
  8. 8.Zargaran D, Zargaran A, Terranova T, et al. Profiling UK injectable aesthetic practitioners: a national cohort analysis. J Plast Reconstr Aesthet Surg. 2023;86:150–154. DOI: 10.1016/j.bjps.2023.06.057
  9. 9.Zargaran D, Zargaran A, Sousi S, et al. Cosmetic business mechanics in London: a cross-sectional analysis and audit of ASA compliance. J Cosmet Dermatol. 2023;22:2520–2527. DOI: 10.1111/jocd.15750
  10. 10.Hopkins ZH, Moreno C, Secrest AM. Influence of social media on cosmetic procedure interest. J Clin Aesthet Dermatol. 2020;13:28.
  11. 11.Montemurro P, Porcnik A, Hedén P, Otte M. The influence of social media and easily accessible online information on the aesthetic plastic surgery practice. Aesthetic Plast Surg. 2015;39:270–277. DOI: 10.1007/s00266-015-0454-3
  12. 12.Geographic Data Service. Index of Multiple Deprivation (IMD)—Dataset. data.geods.ac.uk
  13. 13.gov.scot. Scottish Index of Multiple Deprivation 2020. gov.scot
  14. 14.StatsWales. Welsh Index of Multiple Deprivation. 2019. statswales.gov.wales
  15. 15.Northern Ireland Statistics and Research Agency. Northern Ireland Multiple Deprivation Measure 2017. nisra.gov.uk
  16. 16.Office for National Statistics. Employee earnings in the UK. ons.gov.uk
  17. 17.Zargaran A, Sousi S, Zargaran D, Mosahebi A. TikTok in plastic surgery: a systematic review of its uses. Aesthet Surg J Open Forum. 2023;5:ojad081. DOI: 10.1093/asjof/ojad081
  18. 18.Mironica A, Popescu CA, George D, Tegzeșiu AM, Gherman CD. Social media influence on body image and cosmetic surgery considerations: a systematic review. Cureus. 2024;16:e65626. DOI: 10.7759/cureus.65626
  19. 19.Grand View Horizon. UK Botulinum Toxin Market Size & Outlook, 2030. grandviewresearch.com
  20. 20.Kim J, Kang D. Beyond dollars and scars: the influence of wealth inequality on total expenditure on cosmetic procedures in the United States. J Craniofac Surg. 2024;35:899–902. DOI: 10.1097/SCS.0000000000010049
  21. 21.Alsarraf R, Alsarraf NW, Larrabee WF, Johnson CM. Cosmetic surgery procedures as luxury goods: measuring price and demand in facial plastic surgery. Arch Facial Plast Surg. 2002;4:105–110. DOI: 10.1001/archfaci.4.2.105
  22. 22.Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review. Clin Cosmet Investig Dermatol. 2019;12:223–228. DOI: 10.2147/CCID.S202919
  23. 23.Tudor Hart J. The inverse care law. Lancet. 1971;297:405–412. DOI: 10.1016/S0140-6736(71)92410-X
  24. 24.Zargaran D, Zargaran A, Sousi S, et al. Quantitative and qualitative analysis of individual experiences post botulinum toxin injection — United Kingdom Survey. Skin Health Dis. 2023;3:e265. DOI: 10.1002/ski2.265
  25. 25.Project MUSE. Arrow and the Information Market Failure in Health Care: The Changing Content and Sources of Health Care Information. muse.jhu.edu
  26. 26.GOV.UK. The licensing of non-surgical cosmetic procedures in England: consultation document. gov.uk
  27. 27.Jang HS, Chung KY, Ho Oh B. Complications from cosmetic procedures performed by non-professionals: a case analysis and review of treatments. Korean J Dermatol. 2014;52:222–229.
  28. 28.Holloway V, Manager P, England R. Protecting patients: why tighter regulation is crucial for UK cosmetic surgery. Bull R Coll Surgeons Engl. 2025;107:172–173. DOI: 10.1308/rcsbull.2025.69
  29. 29.Mayer JE, Goldberg DJ. Injuries attributable to cosmetic procedures performed by unlicensed individuals in the United States. J Clin Aesthet Dermatol. 2015;8:35.
  30. 30.Rossi AM, Wilson B, Hibler BP, Drake LA. Nonphysician practice of cosmetic dermatology: a patient and physician perspective of outcomes and adverse events. Dermatol Surg. 2019;45:588–597. DOI: 10.1097/DSS.0000000000001829

Last reviewed: May 2026 · SkinSage content team